Neumentum nabs J&J pain molecules

10 October 2019
neumentum_large

Privately-held US pain specialist Neumentum has entered into a global licensing agreement with Janssen Pharmaceutica and McNeil Consumer Pharmaceuticals, both part of US healthcare giant Johnson & Johnson (NYSE: JNJ), for the rights to an oral analgesic, JNJ-10450232, plus a portfolio of backup compounds.

The target indication for JNJ-10450232, which is neither an opioid nor an NSAID, is for moderate to moderately severe acute pain, and it has already gone through Phase IIa studies.

"There is a real lack of innovation in the pain management space"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical